BAKER BROS ADVISORS LLC Insider Trading $ACAD ACADIA PHARMACEUTICALS INC
Get free email notifications about insider trading for BAKER BROS ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BAKER BROS ADVISORS LLC. BAKER BROS ADVISORS LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in XOMA Corp ($XOMA) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in BELLICUM PHARMACEUTICALS, INC ($BLCM) and 10% Owner in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in Zymeworks Inc. ($ZYME) and Director in Kodiak Sciences Inc. ($KOD) and 10% Owner in Invitae Corp ($NVTA) and Director in IGM Biosciences, Inc. ($IGMS) and 10% Owner in Atreca, Inc. ($BCEL) and in Mirati Therapeutics, Inc. ($MYG) and 10% Owner in Mirati Therapeutics, Inc. ($MYG) and Director in Talis Biomedical Corp ($TLIS) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in Intellia Therapeutics, Inc. ($NTLA) and Director in BeiGene, Ltd. ($BGNE) and Director in Prelude Therapeutics Inc ($PRLD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and in HOOKIPA Pharma Inc. ($HOOK).
BAKER BROS ADVISORS LLC in ACADIA PHARMACEUTICALS INC
Trading Symbol: ACADIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of BAKER BROS ADVISORS LLC: Director
Holdings: 3,476,727 shares
Current Value: $132,776,204
Latest Transaction: Jun 25 2020
$ACAD Market Capitalization: $4.67B
$ACAD Previous Close: $38.19
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of BAKER BROS ADVISORS LLC in ACADIA PHARMACEUTICALS INC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACAD, AGLE, ALXN, BCEL, BGNE, BLCM, BCRX, GHDX, HOOK, IDRA, IGMS, INCY, NTLA, NVTA, KNSA, KOD, MYG, NLTX, PRLD, RYTM, SGEN, TLIS, XOMA, ZYME
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 52.73 | 11,158 | 588,361 | 11,158 | |
Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 6,118 | 0 | 38,440,095 | 38.4 M to 38.4 M (+0.02 %) |
Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 6,118 | 0 | 3,476,727 | 3.5 M to 3.5 M (+0.18 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 34.47 | 42,473 | 1,463,896 | 38,433,977 | 38.4 M to 38.4 M (+0.11 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 34.47 | 3,837 | 132,248 | 3,470,609 | 3.5 M to 3.5 M (+0.11 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.63 | 33,464 | 1,125,465 | 38,391,504 | 38.4 M to 38.4 M (+0.09 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.63 | 3,023 | 101,670 | 3,466,772 | 3.5 M to 3.5 M (+0.09 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.85 | 2,201 | 72,302 | 38,358,040 | 38.4 M to 38.4 M (+0.01 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.85 | 199 | 6,537 | 3,463,749 | 3.5 M to 3.5 M (+0.01 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.61 | 46,225 | 1,507,268 | 38,355,839 | 38.3 M to 38.4 M (+0.12 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.61 | 4,175 | 136,135 | 3,463,550 | 3.5 M to 3.5 M (+0.12 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.94 | 275 | 8,782 | 38,309,614 | 38.3 M to 38.3 M (0.00 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.94 | 25 | 798 | 3,459,375 | 3.5 M to 3.5 M (0.00 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.86 | 93,006 | 3,149,406 | 38,309,339 | 38.2 M to 38.3 M (+0.24 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.86 | 8,402 | 284,512 | 3,459,350 | 3.5 M to 3.5 M (+0.24 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.32 | 24,223 | 782,873 | 38,216,333 | 38.2 M to 38.2 M (+0.06 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.32 | 2,188 | 70,715 | 3,450,948 | 3.4 M to 3.5 M (+0.06 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.19 | 29,624 | 953,620 | 38,192,110 | 38.2 M to 38.2 M (+0.08 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.19 | 2,676 | 86,143 | 3,448,760 | 3.4 M to 3.4 M (+0.08 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.83 | 7,612 | 242,290 | 38,162,486 | 38.2 M to 38.2 M (+0.02 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.83 | 688 | 21,899 | 3,446,084 | 3.4 M to 3.4 M (+0.02 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.74 | 43,212 | 1,371,359 | 38,154,874 | 38.1 M to 38.2 M (+0.11 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.74 | 3,903 | 123,864 | 3,445,396 | 3.4 M to 3.4 M (+0.11 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.00 | 3,913 | 121,285 | 38,111,662 | 38.1 M to 38.1 M (+0.01 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.00 | 353 | 10,941 | 3,441,493 | 3.4 M to 3.4 M (+0.01 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.51 | 631,281 | 19,893,937 | 38,107,749 | 37.5 M to 38.1 M (+1.68 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.51 | 57,022 | 1,796,968 | 3,441,140 | 3.4 M to 3.4 M (+1.68 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.19 | 5,503 | 171,613 | 37,476,468 | 37.5 M to 37.5 M (+0.01 %) |
Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.19 | 497 | 15,499 | 3,384,118 | 3.4 M to 3.4 M (+0.01 %) |
Sep 20 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 40.00 | 1,494,025 | 59,761,000 | 37,470,965 | 36 M to 37.5 M (+4.15 %) |
Sep 20 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 40.00 | 68,475 | 2,739,000 | 3,383,621 | 3.3 M to 3.4 M (+2.07 %) |
Jun 28 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 25.24 | 30,000 | 757,200 | 30,000 | |
Jun 07 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 31,229 | 0 | 102,876 | 71.6 K to 102.9 K (+43.59 %) |
Jun 07 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 31,229 | 0 | 102,876 | 71.6 K to 102.9 K (+43.59 %) |
Jun 07 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 421,756 | 0 | 3,315,146 | 3.7 M to 3.3 M (-11.29 %) |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | J | 0.01 | 1,569 | 16 | 1,569 | |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | J | 0.01 | 1,569 | 16 | 1,569 | |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | J | 0.01 | 10,731 | 107 | 0 | |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 71,647 | 0 | 71,647 | 0 to 71.6 K |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 71,647 | 0 | 71,647 | 0 to 71.6 K |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 489,977 | 0 | 0 | 490 K to 0 (-100.00 %) |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 17.00 | 11,178,823 | 190,039,991 | 35,976,940 | 24.8 M to 36 M (+45.08 %) |
Dec 04 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 17.00 | 585,882 | 9,959,994 | 3,736,902 | 3.2 M to 3.7 M (+18.59 %) |
Sep 24 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 19.09 | 131,007 | 2,501,238 | 24,798,117 | 24.7 M to 24.8 M (+0.53 %) |
Sep 24 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 19.09 | 14,555 | 277,890 | 3,151,020 | 3.1 M to 3.2 M (+0.46 %) |
Sep 24 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 19.01 | 38,207 | 726,353 | 24,667,110 | 24.6 M to 24.7 M (+0.16 %) |
Sep 24 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 19.01 | 4,245 | 80,702 | 3,136,465 | 3.1 M to 3.1 M (+0.14 %) |
Sep 24 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 18.64 | 920,495 | 17,154,897 | 24,628,903 | 23.7 M to 24.6 M (+3.88 %) |
Sep 24 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 18.64 | 102,267 | 1,905,909 | 3,132,220 | 3 M to 3.1 M (+3.38 %) |
Jun 08 2018 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 17.52 | 30,000 | 525,600 | 30,000 | |
Nov 29 2017 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 1.38 | 39,378 | 54,342 | 0 | |
Nov 29 2017 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Payment of Exercise | F | 28.00 | 1,941 | 54,348 | 489,977 | 491.9 K to 490 K (-0.39 %) |
Nov 29 2017 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 1.38 | 39,378 | 54,342 | 491,918 | 452.5 K to 491.9 K (+8.70 %) |
Oct 16 2017 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 1.38 | 1,426,590 | 1,968,694 | 0 | |
Oct 16 2017 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Payment of Exercise | F | 35.40 | 55,457 | 1,963,178 | 23,708,408 | 23.8 M to 23.7 M (-0.23 %) |
Oct 16 2017 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 1.38 | 1,426,590 | 1,968,694 | 23,763,865 | 22.3 M to 23.8 M (+6.39 %) |
Jun 14 2017 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 27.25 | 30,000 | 817,500 | 30,000 | |
Aug 12 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.00 | 1,169,877 | 38,605,941 | 22,337,275 | 21.2 M to 22.3 M (+5.53 %) |
Aug 12 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.00 | 133,153 | 4,394,049 | 3,029,953 | 2.9 M to 3 M (+4.60 %) |
Jun 13 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 39.60 | 26,500 | 1,049,400 | 26,500 | |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 28.55 | 262,253 | 7,486,904 | 21,167,398 | 20.9 M to 21.2 M (+1.25 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 28.55 | 28,647 | 817,826 | 2,896,800 | 2.9 M to 2.9 M (+1.00 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 27.82 | 10,818 | 300,959 | 20,905,145 | 20.9 M to 20.9 M (+0.05 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 27.82 | 1,182 | 32,883 | 2,868,153 | 2.9 M to 2.9 M (+0.04 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 27.72 | 318,969 | 8,840,959 | 20,894,327 | 20.6 M to 20.9 M (+1.55 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 27.72 | 34,844 | 965,782 | 2,866,971 | 2.8 M to 2.9 M (+1.23 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 27.56 | 60,587 | 1,669,705 | 20,575,358 | 20.5 M to 20.6 M (+0.30 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 27.56 | 6,618 | 182,384 | 2,832,127 | 2.8 M to 2.8 M (+0.23 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 26.55 | 28,433 | 755,024 | 20,514,771 | 20.5 M to 20.5 M (+0.14 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 26.55 | 3,106 | 82,478 | 2,825,509 | 2.8 M to 2.8 M (+0.11 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 26.49 | 180,122 | 4,772,224 | 20,486,338 | 20.3 M to 20.5 M (+0.89 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 26.49 | 19,676 | 521,304 | 2,822,403 | 2.8 M to 2.8 M (+0.70 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 26.29 | 13,433 | 353,086 | 20,306,216 | 20.3 M to 20.3 M (+0.07 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 26.29 | 1,467 | 38,560 | 2,802,727 | 2.8 M to 2.8 M (+0.05 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 25.61 | 14,775 | 378,343 | 20,292,783 | 20.3 M to 20.3 M (+0.07 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 25.61 | 1,614 | 41,330 | 2,801,260 | 2.8 M to 2.8 M (+0.06 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 26.35 | 16,057 | 423,057 | 2,799,646 | 2.8 M to 2.8 M (+0.58 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 25.98 | 37,882 | 983,985 | 2,783,589 | 2.7 M to 2.8 M (+1.38 %) |
Apr 01 2016 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 25.92 | 408,607 | 10,593,014 | 2,745,707 | 2.3 M to 2.7 M (+17.48 %) |
Dec 15 2015 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 32.50 | 15,000 | 487,500 | 15,000 | |
Jun 17 2015 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 39.06 | 12,500 | 488,250 | 12,500 |
Page: 1